Literature DB >> 3706232

Risk of primary infection and reinfection with respiratory syncytial virus.

W P Glezen, L H Taber, A L Frank, J A Kasel.   

Abstract

Respiratory syncytial virus is the most important cause of serious lower respiratory tract infection in children. For children followed up from birth in the Houston Family Study, the infection rate was 68.8/100 children less than 12 months of age and 82.6/100 during the second year of life. Virtually all children had been infected at least once by 24 months of age, and about one half had experienced two infections. Although lower respiratory tract disease (LRD) was common (22.4/100 during year 1 and 13.0/100 during year 2), most children had only one LRD illness. The risk of reinfection was inversely related to the level of neutralizing antibodies in the serum. Reinfection illnesses were generally mild, and risk of reinfection decreased to only 33.3/100 during year 4. Studies of children with LRD and surveys of hospitalizations provide the basis for an estimate of the number of children hospitalized each year during the respiratory syncytial virus epidemics. Almost 100,000 children in the United States experience an illness of sufficient severity to require hospitalization.

Entities:  

Mesh:

Year:  1986        PMID: 3706232     DOI: 10.1001/archpedi.1986.02140200053026

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  521 in total

Review 1.  Current research on respiratory viral infections: Third International Symposium.

Authors:  A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal:  Antiviral Res       Date:  2001-06       Impact factor: 5.970

2.  Deep sequencing of RSV from an adult challenge study and from naturally infected infants reveals heterogeneous diversification dynamics.

Authors:  Jessica W Lau; Young-In Kim; Ryan Murphy; Ruchi Newman; Xiao Yang; Michael Zody; John DeVincenzo; Yonatan H Grad
Journal:  Virology       Date:  2017-08-03       Impact factor: 3.616

3.  Respiratory syncytial virus immunoprophylaxis: impact on epidemiology.

Authors:  N N Dougherty; H C Meissner
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.022

4.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

5.  Evaluation of two rapid detection assays for identification of respiratory syncytial virus in nasopharyngeal secretions of young children.

Authors:  C Wyder-Westh; A Duppenthaler; M Gorgievski-Hrisoho; C Aebi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-08       Impact factor: 3.267

Review 6.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

7.  Methods for monitoring dynamics of pulmonary RSV replication by viral culture and by real-time reverse transcription-PCR in vivo: Detection of abortive viral replication.

Authors:  Marina S Boukhvalova; Kevin C Yim; Gregory A Prince; Jorge C G Blanco
Journal:  Curr Protoc Cell Biol       Date:  2010-03

8.  Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.

Authors:  Sujin Lee; Robert S Mittler; Martin L Moore
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

9.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Authors:  Eileen Goodwin; Morgan S A Gilman; Daniel Wrapp; Man Chen; Joan O Ngwuta; Syed M Moin; Patricia Bai; Arvind Sivasubramanian; Ruth I Connor; Peter F Wright; Barney S Graham; Jason S McLellan; Laura M Walker
Journal:  Immunity       Date:  2018-02-03       Impact factor: 31.745

Review 10.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.